In-Hospital and 1-Year Mortality Trends in a National Cohort of US Veterans with Acute Kidney Injury.

医学 危险系数 急性肾损伤 置信区间 回顾性队列研究 肾脏疾病 比例危险模型 内科学 队列 急诊医学 肌酐 队列研究
作者
Ryann Sohaney,Huiying Yin,Vahakn Shahinian,Rajiv Saran,Nilka Ríos Burrows,Meda E Pavkov,Tanushree Banerjee,Chi-yuan Hsu,Neil Powe,Diane Steffick,Kara Zivin,Michael Heung
出处
期刊:Clinical Journal of The American Society of Nephrology [American Society of Nephrology]
卷期号:17 (2): 184-193
标识
DOI:10.2215/cjn.01730221
摘要

AKI, a frequent complication among hospitalized patients, confers excess short- and long-term mortality. We sought to determine trends in in-hospital and 1-year mortality associated with AKI as defined by Kidney Disease Improving Global Outcomes consensus criteria.This retrospective cohort study used data from the national Veterans Health Administration on all patients hospitalized from October 1, 2008 to September 31, 2017. AKI was defined by Kidney Disease Improving Global Outcomes serum creatinine criteria. In-hospital and 1-year mortality trends were analyzed in patients with and without AKI using Cox regression with year as a continuous variable.We identified 1,688,457 patients and 2,689,093 hospitalizations across the study period. Among patients with AKI, 6% died in hospital, and 28% died within 1 year. In contrast, in-hospital and 1-year mortality rates were 0.8% and 14%, respectively, among non-AKI hospitalizations. During the study period, there was a slight decline in crude in-hospital AKI-associated mortality (hazard ratio, 0.98 per year; 95% confidence interval, 0.98 to 0.99) that was attenuated after accounting for patient demographics, comorbid conditions, and acute hospitalization characteristics (adjusted hazard ratio, 0.99 per year; 95% confidence interval, 0.99 to 1.00). This stable temporal trend in mortality persisted at 1 year (adjusted hazard ratio, 1.00 per year; 95% confidence interval, 0.99 to 1.00).AKI associated mortality remains high, as greater than one in four patients with AKI died within 1 year of hospitalization. Over the past decade, there seems to have been no significant progress toward improving in-hospital or long-term AKI survivorship.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
田様应助Isabel采纳,获得10
刚刚
gezid完成签到 ,获得积分10
刚刚
1秒前
1秒前
niu1发布了新的文献求助10
1秒前
Intro发布了新的文献求助10
1秒前
舒服的冬天完成签到,获得积分10
2秒前
Helical给Helical的求助进行了留言
2秒前
甜蜜晓绿完成签到,获得积分10
2秒前
3秒前
钱多多完成签到,获得积分10
3秒前
baekhyun完成签到,获得积分20
3秒前
3秒前
dpp发布了新的文献求助10
3秒前
今今完成签到,获得积分10
3秒前
4秒前
4秒前
4秒前
5秒前
打打应助无情的白桃采纳,获得10
5秒前
香蕉觅云应助与光同晨采纳,获得10
6秒前
6秒前
小蘑菇应助clm采纳,获得10
6秒前
yhnsag完成签到,获得积分10
6秒前
Lin完成签到,获得积分10
6秒前
6秒前
7秒前
7秒前
8秒前
Rain发布了新的文献求助10
8秒前
butiflow完成签到,获得积分10
8秒前
8秒前
8秒前
9秒前
务实的唇膏完成签到,获得积分10
9秒前
Will完成签到,获得积分10
9秒前
9秒前
Micky完成签到,获得积分10
9秒前
ape发布了新的文献求助10
9秒前
十七发布了新的文献求助10
10秒前
高分求助中
Continuum Thermodynamics and Material Modelling 3000
Production Logging: Theoretical and Interpretive Elements 2700
Social media impact on athlete mental health: #RealityCheck 1020
Ensartinib (Ensacove) for Non-Small Cell Lung Cancer 1000
Unseen Mendieta: The Unpublished Works of Ana Mendieta 1000
Bacterial collagenases and their clinical applications 800
El viaje de una vida: Memorias de María Lecea 800
热门求助领域 (近24小时)
化学 材料科学 生物 医学 工程类 有机化学 生物化学 物理 纳米技术 计算机科学 内科学 化学工程 复合材料 基因 遗传学 物理化学 催化作用 量子力学 光电子学 冶金
热门帖子
关注 科研通微信公众号,转发送积分 3527723
求助须知:如何正确求助?哪些是违规求助? 3107826
关于积分的说明 9286663
捐赠科研通 2805577
什么是DOI,文献DOI怎么找? 1539998
邀请新用户注册赠送积分活动 716878
科研通“疑难数据库(出版商)”最低求助积分说明 709762